Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.

Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Abstract Text:

Pimecrolimus and tacrolimus are calcineurin inhibitors used for the topical treatment of atopic dermatitis. Although structurally similar, they display specific differences including higher lipophilicity and lower skin permeation of pimecrolimus. The aim of the present study was to understand the reason for the differences in skin permeation; in addition, plasma protein binding of the two drugs was analyzed side by side as a basis for comparison of systemic exposure to free drug. Permeation of pimecrolimus and tacrolimus through a silicon membrane was found to be similar; therefore, we assumed that differences in skin permeation could be caused by differences in affinity to skin components. To test this hypothesis, we investigated binding of pimecrolimus and tacrolimus to a preparation of soluble human skin proteins. One binding protein of approximately 15 kDa, probably corresponding to macrophilin12, displayed a similar binding capacity for pimecrolimus and tacrolimus. However, less specific, nonsaturating binding to other proteins was approximately 3-fold higher for pimecrolimus. Because of the high local drug concentration after topical administration, the unspecific, high-capacity binding is probably dominating the permeation through skin. In plasma both drugs bound predominantly to lipoproteins, which may affect disposition differently from albumin binding. The unbound fraction of pimecrolimus in human plasma was approximately 9-fold lower compared with that of tacrolimus (0.4 +/- 0.1 versus 3.7 +/- 0.8%). In conclusion, these results provide an explanation for the observed lower systemic exposure to pimecrolimus than to tacrolimus after topical application and suggest that differences in systemic exposure to free drug might be even more pronounced.

Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Drug metabolism and disposition: the biological fa

VOLUME: 36

Page Numbers: 1812-8

Journal Abbreviation: Drug Metab. Dispos.

ISSN: 1521-009X

DAY: 4

MONTH: 06

YEAR: 2008

Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 9421550

Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.

AFFILIATION: Novartis Pharma AG, Basel, Switzerland. markus.weiss@novartis.com

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Drug Metab Dispos

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application Related Publications

• Binding of pimecrolimus and tacrolimus to skin and plasma proteins: implications for systemic exposure after topical application.
• Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
• GS-4104 (Gilead Sciences Inc).
• NBD-labeled derivatives of the immunomodulatory drug FTY720 as tools for metabolism and mode of action studies.
• Sphingosine kinase type 2 is essential for lymphopenia induced by the immunomodulatory drug FTY720.
• [Analytic developmental blood serum examinations in female genital carcinoma (paper electrophoresis).]
• [Contribution to the treatment of the pelvic presentation delivery. (Clinical experience report)]
• [Differential diagnosis of genital tumors & floating spleens.]
• [HABITUAL STILLBIRTHS IN ADVANCED DIFFUSE SCLERODERMIA.]
• [On a congenital skull impression not explainable by labor mechanics in a newborn infant.]
• [Unusual angioma-like vascular hyperplasia in vagina and uterus.]